Please login to the form below

Not currently logged in
Email:
Password:

Gyroscope Therapeutics appoints CEO

Dr Soraya Bekkali joins from biotech firm Lysogene

Ophthalmology group Gyroscope Therapeutics has appointed Dr Soraya Bekkali as its chief executive officer and director of its board.

She has over 20 years’ industry experience and moves to the London-based biotech firm from Lysogene where she served as the French biotechnology company's senior vice president and chief medical officer.

She said: “I am excited to be joining Gyroscope at the company’s founding stage to advance new genetically-defined therapies for the treatment of debilitating eye diseases such as age-related macular degeneration.

“Gyroscope has a unique translational approach to tackling complex diseases such as dry AMD for which there are no therapies today.”

Dr Bekkali’s previous leadership positions include global head of the ophthalmology business unit at Sanofi, where she led its ophthalmology strategy towards ocular gene therapy and set up a multidisciplinary team.

Chris Hollowood, chairman of the board and chief investment office at Syncona, said: “We are extremely pleased to appoint Soraya and look forward to her leadership and extensive gene therapy and ophthalmology clinical experience driving the company forward.”

10th October 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics